Articles tagged with Drug Discovery
Researchers at Duke University have developed a technique to capture RNA molecules in precise images, revealing new opportunities for drug discovery. The method identifies potential anti-HIV compounds from millions of possibilities, showcasing its accuracy and potential to treat various ailments.
Eight out of ten transformative medicines in the US between 1985 and 2009 originated from fundamental discoveries, with an average time to approval of 30 years. Curiosity-driven science is essential for discovering new medicines.
Researchers have discovered an alternative strategy to combat antimicrobial resistance by repositioning colloidal bismuth subcitrate, which effectively paralyzes multi-resistant superbugs and suppresses the development of antibiotic resistance. The findings offer a promising new approach to treat deadly infections caused by CRE and CRKP.
Researchers at Nagoya University have successfully determined the crystal structure of the gastric proton pump, a key enzyme in stomach acid secretion. The study sheds light on how the pump expels hydrogen ions into the stomach despite its acidic environment.
Biogerontology Research Foundation's Chief Science Officer, Professor Alexander Zhavoronkov, will share his projections on how AI is set to revolutionize biopharma for aging and biomarker discovery. He will reveal the latest progress in AI and drug discovery at Pioneers18 in Vienna.
Researchers at Trinity College Dublin have discovered a potential 'off-switch' for inflammation by identifying the molecule itaconate, which can block production of inflammatory factors and protect against lethal inflammation. This breakthrough could lead to new anti-inflammatory medicines for diseases such as arthritis and heart disease.
A study discovered that an experimental drug connected to fat regulation prevents the formation of kidney stones in mice. The researchers found that the β3-agonist reduced inflammation in kidneys by consuming free fatty acids, potentially preventing both obesity and kidney stones. Further studies are needed to confirm these findings.
LSU researchers developed a computer-assisted drug repositioning process to identify existing drugs for rare diseases. They matched protein structures and functions with existing drug interactions to help patients receive effective treatment.
Researchers at TSRI have developed a new desulfonylative cross-coupling reaction that simplifies the synthesis of drug-like molecules, including alkyl-fluorinated compounds. This method paves the way for creating new types of compounds and facilitating the synthesis of pharmaceuticals.
University of Alberta researchers have found the Ebola polymerase enzyme, which may lead to more effective research and better treatments for the often fatal infection. The discovery allows for the study of Ebola inhibitors in any lab environment, accelerating the search for antiviral medicines.
Researchers at Australian National University have identified molecular similarities across six pharmaceutical drugs to reduce unwanted side effects. The study, published in Proceedings of the National Academy of Sciences, aims to inform future scientists on how to design more specific drugs with fewer side effects.
Researchers propose roadmap for making humans resistant to radiation and stress damage, with a focus on radioresistance. The strategies aim to maximize productive life years in space, addressing challenges like high-LET radiation.
McMaster University engineers have developed a printed paper-based device that speeds up and improves the accuracy of drug screening. The technology uses a printable hydrogel to filter out inaccurate results, reducing the time and cost associated with drug discovery.
Researchers at U of T have designed a new antimicrobial material to minimize recurrent caries under fillings, affecting 100 million patients annually. The novel material packs 50 times more bacteria-fighting drugs than traditional options, offering a potential solution to this common dental problem.
Researchers at University of Toronto have developed technology for creating durable disease-fighting molecules that can last longer in the body, reducing frequent drug injections. Mirror-image versions of existing drugs, such as GLP1 and PTH, have been created using computational approach, showing longer-lasting effects on cells.
Researchers at University of Bristol have successfully trapped objects larger than the wavelength of sound in an acoustic tractor beam, paving the way for levitation of humans. The discovery uses rapidly fluctuating acoustic vortices, which are stabilised by controlling the rate of rotation.
Researchers at the University of Kansas have developed a method to screen millions of human antibodies for rapid therapeutic discovery, overcoming limitations of single-cell cloning. The breakthrough technology identifies highly potent antibodies and provides insights into human immune responses to vaccines and infections.
A novel deep-learning based hematological human aging clock predicts the biological age of individual patients with high accuracy. The model outperforms chronological age in predicting all-cause mortality, highlighting population-specific patterns of aging.
A new machine-learning model can accurately predict protein-drug interactions based on a few reference experiments or simulations, accelerating the screening of candidate molecules thousands of times over. The algorithm can also tackle materials-science problems, revolutionizing materials and chemical modeling.
Researchers at The University of Manchester have discovered that uranium can perform reactions previously thought impossible, opening the door to new ways of producing materials and chemicals. This breakthrough could lead to the creation of truly biodegradable hard plastic and new medicines.
Aric Rogers' research discovered that NMD plays a critical role in extending lifespan under dietary restriction conditions. The grant will help expedite the development of 'DR mimetics,' drugs that mimic the effects of DR on longevity, potentially leading to new therapies.
The new Connectivity Map includes over 1.3 million gene expression profiles from multiple cell lines treated with chemical or genetic perturbations, enabling the study of small molecule and gene function. This expanded resource accelerates drug discovery efforts by predicting how small molecules work and discovering compounds with spec...
Researchers have validated five new genes responsible for Amyotrophic Lateral Sclerosis (ALS), a fatal neurological disorder. The study uses AI-powered technology to accelerate the discovery of new treatments by identifying key proteins linked to the disease.
A study published in the Journal of Consumer Psychology found that consumers are more likely to engage in dishonest behavior, such as shoplifting or piracy, if they perceive a company as harming the environment or people. This effect occurs even when consumers have not personally had a bad experience with the company.
A UCL-led study found that inhibiting RNA polymerase III, a common enzyme in all animals, extends the lifespans of yeast cells and animals by an average of 10%. This discovery may lead to targeted anti-aging therapies, similar to the effects of rapamycin.
Researchers from Insilico Medicine and BitFury Group present a blockchain-based life data interchange system to decentralize and accelerate biomedical research. The system utilizes deep learning technologies to analyze human life data, reducing biases and democratizing healthcare access.
A new technique, ligand-accelerated non-directed C-H functionalization, enables the late-stage modification of complex drug molecules to improve therapeutic properties. Researchers used a special ligand molecule called 2-pyridone to enhance palladium's reactivity with targeted C-H bonds.
Scientists at the University of Edinburgh have identified two molecules, SMAD2 and SMAD3, that enhance cellular reprogramming efficiency. This breakthrough could accelerate production of induced pluripotent stem cells for studying diseases like multiple sclerosis and Parkinson's disease.
Researchers have discovered that glatiramer acetate, a widely used multiple sclerosis treatment, can also effectively kill certain multi-resistant bacteria. This breakthrough opens up new possibilities for treating cystic fibrosis patients and may even provide insight into the underlying causes of multiple sclerosis.
A new study by Sanford Burnham Prebys Medical Discovery Institute found that chloroquine, an anti-malarial drug, reduces the transmission of Zika virus from mother to fetus. The research suggests that chloroquine may be effective in treating and preventing Zika infections.
A new model proposes returning control over human life data to patients, accelerating biomedical research through a secure and transparent distributed personal data marketplace utilizing blockchain and deep learning technologies. This approach can resolve challenges faced by regulators and improve patient satisfaction.
Anita Mattson's research focuses on naturally occurring molecules known as dimeric chromanones, which have high biological activity and may become powerful dual-action treatments for drug-resistant cancers. Her goal is to develop a new class of catalysts using silanediols to control the synthesis of these compounds.
A new technique using blue LED lights and catalysts reduces the time to create radioactive molecules from months to hours, accelerating the arrival of new drugs to the marketplace. This innovation has the potential to bring medicines to patients much faster than before.
Researchers at Rutgers University have identified a protein complex called TldD that activates the antibiotic microcin B17 by removing its protective coating. This discovery could lead to the development of new antibacterial agents and drugs to combat toxins.
Insilico Medicine showcases its use of artificial intelligence to identify disease targets, generate molecular structures, and track interventions for metabesity. The company aims to prevent metabolic-rooted disorders such as diabetes and dementia.
A new $1.85 million grant will support a Phase 2 clinical trial of AMX0035, a combination of sodium phenylbutyrate and tauroursodeoxycholic-acid, to test its effectiveness in slowing or stopping brain cell death in people with mild cognitive impairment or Alzheimer's disease.
A new combination therapy using registered drugs albendazole and antibiotics has dramatically shortened treatment time for lymphatic filariasis and onchocerciasis, reducing it from weeks to just seven days. This breakthrough could accelerate elimination of these debilitating diseases, prioritized by the UN's Sustainable Development Goals.
A new AI model called druGAN enables the generation of novel molecules with desired properties, surpassing previous GAN-based approaches. The model uses reinforcement learning to generate effective molecular graphs, paving the way for improved pharmaceuticals.
Researchers demonstrate an engineering approach to combine four drugs and control parasitic worms, a major breakthrough in treating nematode infections. The technique, developed by Chih-Ming Ho, uses a feedback system to quickly identify potent drug combinations that are effective on a small-animal model organism.
Researchers studied HIV drug combinations to understand why some drugs act synergistically while others do not. They found that virus protein mutations and host cell receptor density affect synergy, highlighting the need for personalized treatment approaches.
Scientists have developed a new sensor that can detect minute concentrations of methamphetamine and amphetamine in urine, allowing for real-time drug screening. The sensor uses a pumpkin-shaped molecule to bind with the drugs, triggering an electrical signal that appears on a smartphone screen.
The Children's Tumor Foundation and PLOS ONE are collaborating on a new funding program in neurofibromatosis (NF) research, integrating the Registered Reports model to enhance rigor, reproducibility, and transparency. The partnership aims to accelerate transparent science and eliminate publication bias.
Researchers at Dartmouth College developed a technique to produce synthetic steroids, paving the way for new drug discoveries. The process reduces time and expense to develop therapeutics from rare, mirror-image isomers of naturally occurring steroid structures.
The article presents a series of grid-based computational technologies for in silico virtual screening and molecular design of new drugs. The technologies use original CoMIn software to analyze molecular structure in terms of intermolecular interactions potentials and quantum functions.
A study by the European Center of Pharmaceutical Medicine at the University of Basel compared regulatory requirements for new drugs across 12 countries, revealing significant variations. Harmonization could improve efficiency and reduce prices, making innovative drugs available faster.
Researchers used baker's yeast to test natural compounds from soil-based bacteria, discovering diverse agents affecting various cell processes. These compounds may be used to treat conditions like Alzheimer's, Parkinson's, and cancer.
Researchers at the University of Sheffield have discovered that methotrexate, an arthritis drug, shows promise in treating Polycythemia Vera, a type of blood cancer affecting 3,000 people annually. The treatment has been shown to suppress JAK/STAT pathway activation and normalise blood counts in mice models.
Researchers have discovered a potential new treatment for delayed neuropathy caused by insecticides or chemical exposure. The study identified the TRPA1 channel as responsible for the condition and found that duloxetine and ketotifen alleviate symptoms in animal models.
Researchers at Binghamton University have developed a new drug that demonstrates superior anti-parkinsonian efficacy over current medications. The compound, D-512, provides longer symptom relief and prolongs the time window in which benefits are shown.
A new method developed by an international research team uses yeast cells to speed up drug discovery by linking compounds to cellular processes they target. The study found that natural compounds derived from soil microbes hold promise as potential medicines against various diseases, including infections and cancer.
Researchers at the University of Wisconsin-Madison have developed an automated screening test to create all-chemical replacements for traditional stem cell growth materials. This innovation enables wider use of stem cells in regenerative medicine, drug discovery, and testing environmental chemicals for vascular toxicity.
Griffith University researchers used Australia's fastest camera to measure the time it takes for molecules to break apart, achieving a record-breaking 15 millionth of a billionth of a second. This breakthrough could help design new molecules for materials science and drug discovery.
Scientists have developed a systematic approach to screen for molecules produced by molds, finding 17 new natural products in three species. The technology, called FAC-MS, uses genomics and data analytics to identify gene clusters that produce valuable chemicals.
Researchers from Novartis and collaborators have discovered a novel drug candidate, KDU731, to combat the protozoan parasite Cryptosporidium, which causes cryptosporidiosis. This breakthrough offers hope for new treatment options against this disease, which currently has no effective treatments or vaccines.
Researchers have developed a new approach to create integration-free, Myc- and Lin28-free human induced pluripotent stem cells. This breakthrough method reduces the neoplastic risk associated with IPSC generation, enabling their utility in regenerative medicine and personalized medicine.
The Biogerontology Research Foundation will present its work on applying artificial intelligence and deep learning to combat aging and age-related disease. The foundation has published seminal papers demonstrating the potential of these approaches to accelerate drug discovery and development, reducing costs and risks.
The Biogerontology Research Foundation is helping to develop artificial intelligence for accelerated drug discovery in aging and age-related diseases. Researchers have made significant progress in using deep learning-based approaches to characterize biomarkers of ageing and predict the chronological age of patients.
Insilico Medicine will showcase its pioneering work in applying deep learning techniques to drug discovery, biomarker development, and aging research. The company's presentation highlights the applications of Generative Adversarial Networks (GANs) in oncology and infectious diseases.
A new compound, MMV390048, has been discovered and shown to be effective against resistant strains of the malaria parasite across its entire lifecycle. The research holds great promise for a single-dose cure, potentially contributing to the eradication of malaria.
Researchers have created a technique to encase proteins in silica cages, keeping them intact at high temperatures up to 100°C. This method, called ensilication, has the potential to revolutionize vaccine storage and transportation, particularly for remote or resource-constrained areas.